We are pleased to celebrate an important milestone achieved by one of our members, China National Biotec Group (CNBG), whose subsidiary, Wuhan Institute of Biological Products Co., Ltd. (WIBP), has successfully developed the innovative preventive biologic product: Reassortant Rotavirus Vaccine, Live, Oral, Hexavalent (Vero Cell), which has officially received regulatory approval from China’s National Medical Products Administration (NMPA)!
As the first rotavirus vaccine to cover six serotypes (G1, G2, G3, G4, G8 and G9) — which together account for over 90% of circulating strains — Rotasiro® represents an important advancement in the prevention of infant diarrheal diseases, offering broader protection for early childhood health.
Rotavirus remains the leading cause of severe diarrhea in children under five worldwide, claiming approximately 220,000 young lives annually. With an efficacy of 85.72% against severe acute gastroenteritis caused by the rotavirus infection and approval for infants 6–36 weeks on a 3-dose oral schedule, Rotasiro® offers broader, easier-to-deliver protection for early childhood immunization programs.
With an annual production capacity of 24 million doses supported by intelligent manufacturing facilities, WIBP is contributing to sustainable global supply and efforts to reduce child mortality caused by rotavirus.
Congratulations, CNBG on this achievement! At DCVMN, we remain steadfast in supporting our members’ efforts to expand access to life-saving vaccines. Together, we are ensuring that scientific innovation benefits every child, everywhere-paving the way for healthier futures, free from preventable diseases.
